May 13, 2021
New Podcast Episode: The Impact of Waiving IP Protections for COVID-19 Related Drugs and Products
It’s The AAF Exchange — your source for clear, data-driven insight into today’s economic and domestic policy issues.
In our latest episode, AAF’s Data and Policy Analyst Tom Lee and Director of Health Care Policy Christopher Holt discuss the Biden Administration’s decision to support waiving certain intellectual property (IP) protections for COVID-19 related drugs and products. They explain why waiving some IP protections will not increase vaccine availability, assess how waiving IP protections could have long-term impacts on innovation and drug development, and they consider what is driving this proposal.
AAF products mentioned in today’s episode:
- Lee and Holt argue that waiving TRIPS will do nothing to increase vaccine production and instead will create a whole new set of trade policy challenges. Read the analysis here.
- In a recent Weekly Checkup, Holt writes that IP protections are not limiting vaccine availability but waiving them could have long-term implications for innovation. Subscribe to the Weekly Checkup here, out every Friday morning!
Whether you’re working from home or taking a walk, The AAF Exchange will keep you up to speed on today’s most pressing policy issues.